The delay in the Phase 2b trial of Gritstone bio's next-generation COVID-19 vaccine to Fall 2024, aimed at enhancing the trial's regulatory utility by using fully GMP-grade raw materials, could potentially dampen investor sentiment in the short term due to the extended timeline. However, the focus on quality and regulatory utility could be seen as a positive move for the long-term success of the vaccine.